Daiichi Sankyo
-
Merck Missed on Seagen, But Comes Back With Potential $22B Daiichi ADC Deal
After paying $4 billion up front, Merck will share in the development and commercialization of three Daiichi Sankyo cancer drugs in the red-hot field of antibody drug conjugates, or ADCs. The most advanced of them is on track for an FDA submission in 2024.
-
AstraZeneca, Daiichi Cancer Drug’s Phase 3 Results Clouded by Toxicity Concerns
An AstraZeneca and Daiichi Sankyo cancer drug achieved one of the main goals of a Phase 3 study in non-small cell lung cancer. But patient deaths were also reported in the study, and the companies disclosed few details about them.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
AstraZeneca, Daiichi Drug Shows Signs It Could Treat a Wide Range of Tumor Types
The HER2 protein targeted by the approved cancer drug Enhertu is found on a wide range of tumors. Interim Phase 2 data reported at the annual meeting of the American Society of Clinical Oncology suggest the AstraZeneca and Daiichi Sankyo drug has potential to treat many of these cancers.
-
AstraZeneca & Daiichi drug wins another FDA approval, this time in lung cancer
On the heels of receiving a landmark FDA approval in breast cancer, AstraZeneca and Daiichi Sankyo drug Enhertu won an additional approval in non-small cell lung cancer. The decision makes the drug the first targeted NSCLC therapy addressing the cancer protein HER2.
-
FDA approval of AstraZeneca drug is first for a new group of breast cancer patients
Enhertu, a breast cancer drug from AstraZeneca and Daiichi Sankyo, is now FDA approved for treating patients whose tumors express low levels of the protein HER2. The decision makes the infused therapy the first targeted treatment for this new category of breast cancer patients.
-
AstraZeneca, Daiichi Sankyo have high hopes for drug that goes low in breast cancer
During the annual meeting of the American Society of Clinical Oncology, AstraZeneca and Daiichi Sankyo reported pivotal clinical trial data showing that their partnered cancer drug Enhertu can treat a group of patients previously thought to be out of reach for a targeted therapy. The results suggest use of this FDA-approved drug could significantly expand to more breast cancer patients.
-
AstraZeneca, Daiichi Sankyo sign $6B deal for antibody-drug conjugate
The companies will share development and commercialization of DS-1062 in solid tumors. They already have a similar deal in place, the $6.9 billion agreement signed last year for another ADC, the HER2-positive breast cancer drug Enhertu.
-
AstraZeneca, Daiichi Sankyo win accelerated approval for breast cancer drug
The drug, Enhertu, is the subject of an ongoing legal dispute between Daiichi Sankyo and Seattle Genetics, which alleges that the Tokyo-based drugmaker used its technology. The two had a partnership from 2008-2015.
-
Daiichi Sankyo sues Seattle Genetics over antibody-drug conjugate technology
Seattle Genetics alleges that the Japanese drugmaker’s DS-8201 uses a linker and other technology that improve on the U.S. company’s own technology. The drug is also the subject of a $7 billion partnership with AstraZeneca.
-
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.
-
FDA turns down approval for Daiichi Sankyo leukemia drug
The outcome was not surprising, in light of a negative vote by an FDA expert panel last month, but an investigator in the study criticized the agency’s approach as being based on a poor understanding of acute myeloid leukemia.
-
FDA expert panel questions Daiichi Sankyo leukemia drug data ahead of meeting
A company spokesperson said the company was working to address the agency’s concerns about the drug, quizartinib, for FLT3-mutated acute myeloid leukemia.
-
AstraZeneca, Daiichi Sankyo’s $6.9B breast cancer drug partnership bears fruit in less than two months
The companies announced the partnership in March to develop trastuzumab deruxtecan, for which they plan to file approval later this year based on the successful Phase II study.